Research
Molecular
Novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs) have insulin-sensitizing properties through a weight-independent action.
DACRAs may offer new treatment options for improving insulin sensitivity.
StrongSupportsmedium confidence
On the horizon are novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs), which elicit weight-loss, but also have insulin-sensitizing properties through a weight-independent action.
Why this rating
The abstract discusses the potential of new drug candidates in detail.
Source
Targeting the root cause of obesity-related comorbidities through weight independent and dependent actions on insulin sensitivity: Benefits of dual amylin and calcitonin receptor agonists
Anna Thorsø Larsen et al. · Biomedicine & Pharmacotherapy · 2025
DOI 10.1016/j.biopha.2025.118388
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →